Summary
Bristol-Myers Squibb Company (BMY) reported increased net sales for the second quarter and first half of 2009, driven by strong performance in key products like PLAVIX* and ABILIFY*. Net earnings also saw a significant increase, benefiting from sales growth, improved gross margins due to manufacturing efficiencies and cost-saving initiatives (Productivity Transformation Initiative - PTI), and favorable foreign exchange impacts. The company continues to execute its strategy to transform into a next-generation biopharmaceutical company, which includes investing in R&D and focusing on specialty and biologic medicines. A notable event was the initial public offering (IPO) of its subsidiary Mead Johnson Nutrition Company in February 2009, in which BMY retains an 83.1% interest. The company also announced a definitive merger agreement to acquire Medarex for approximately $2.4 billion, expected to close in the third quarter of 2009. Financially, BMY maintained a significant level of working capital. While investing activities showed a net outflow due to marketable security purchases, the company generated positive cash flow from operations. The company's liquidity is considered sufficient to cover its operational needs, capital expenditures, and dividends. The report also detailed ongoing legal proceedings, particularly concerning PLAVIX* patent litigation, which could materially impact future sales and financial condition if market exclusivity is lost. Investors should note the continued growth of key pharmaceutical products, the strategic shift towards biopharmaceuticals, the impact of the Mead Johnson IPO, and the potential impact of the Medarex acquisition. The company's ongoing cost-saving initiatives (PTI) are contributing positively to margins and profitability.
Financial Highlights
53 data points| Revenue | $4.67B |
| Cost of Revenue | $1.23B |
| Gross Profit | $3.44B |
| R&D Expenses | $811.00M |
| SG&A Expenses | $922.00M |
| Operating Expenses | $3.14B |
| Operating Income | $880.00M |
| Interest Expense | $42.00M |
| Net Income | $983.00M |
| EPS (Basic) | $0.49 |
| EPS (Diluted) | $0.49 |
Key Highlights
- 1Net sales increased by 3% year-over-year for both the three and six months ended June 30, 2009, driven by key products like PLAVIX* (up 11% and 10% respectively) and ABILIFY* (up 22% and 25% respectively).
- 2Net earnings attributable to Bristol-Myers Squibb Company increased by 29% for the quarter and 14% for the year-to-date period, reflecting sales growth, improved gross margins (up to 73% from 68%), and cost efficiencies from the Productivity Transformation Initiative (PTI).
- 3The company completed the initial public offering (IPO) of its subsidiary Mead Johnson Nutrition Company in February 2009, retaining an 83.1% interest, which contributed to financial flexibility.
- 4BMY announced a definitive agreement to acquire Medarex for approximately $2.4 billion, expected to close in Q3 2009, demonstrating a commitment to strategic growth through acquisition.
- 5Operating cash flow remained strong, providing $1.25 billion for the six months ended June 30, 2009, supporting investments and operations.
- 6Research and development expenses remained stable year-over-year for the quarter but increased by 9% for the year-to-date period, reflecting ongoing investment in the product pipeline.
- 7The company is actively managing its legal and patent landscape, particularly concerning PLAVIX*, with ongoing litigation to protect market exclusivity, the outcome of which could be material to future financial results.